SubHero Banner

Cyramza® (ramucirumab) – Expanded indication

May 29, 2020 - Eli Lilly announced the FDA approval of Cyramza (ramucirumab), in combination with erlotinib, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.

Download PDF